We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02963350
Recruitment Status : Approved for marketing
First Posted : November 15, 2016
Last Update Posted : July 24, 2017
Sponsor:
Information provided by (Responsible Party):

November 9, 2016
November 15, 2016
July 24, 2017
 
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
  • To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial.
  • To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.
Not Provided
Expanded Access
Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
Not Provided
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
Germany,   Italy,   United Kingdom,   United States
 
 
NCT02963350
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Not Provided
Study Director: Jessica Cohen Pfeffer, MD Medical Monitor
BioMarin Pharmaceutical
July 2017